Laboratory Detection of Extended-Spectrum β-Lactamases (ESBLs)
- What are extended-spectrum ß-lactamases?
- Why should clinical laboratory personnel be concerned about detecting these enzymes?
- How can clinical laboratory personnel screen for ESBL production in bacteria?
- How can clinical laboratory personnel confirm ESBL production?
- How should laboratory personnel test for cefotaxime and ceftazidime in combination with clavulanic acid?
- What quality control organisms should laboratories use for ESBL testing?
- Can an ESBL be present in an isolate of K. pneumoniae that is resistant to ceftazidime and/or cefotaxime, but demonstrates no clavulanic acid effect in the phenotypic confirmatory test?
- How should cephalosporin and penicillin results be reported?
- Do isolates other than K. pneumoniae, K. oxytoca, or E. coli produce ESBLs?
ESBLs are enzymes that mediate resistance to extended-spectrum (third generation) cephalosporins (e.g., ceftazidime, cefotaxime, and ceftriaxone) and monobactams (e.g., aztreonam) but do not affect cephamycins (e.g., cefoxitin and cefotetan) or carbapenems (e.g., meropenem or imipenem).
The presence of an ESBL-producing organism in a clinical infection can result in treatment failure if one of the above classes of drugs is used. ESBLs can be difficult to detect because they have different levels of activity against various cephalosporins. Thus, the choice of which antimicrobial agents to test is critical. For example, one enzyme may actively hydrolyze ceftazidime, resulting in ceftazidime minimum inhibitory concentrations (MICs) of 256 µg/ml, but have poor activity on cefotaxime, producing MICs of only 4 µg/ml. If an ESBL is detected, all penicillins, cephalosporins, and aztreonam should be reported as resistant, even if in vitro test results indicate susceptibility (1).
The National Committee for Clinical Laboratory Standards (NCCLS) has developed broth microdilution and disk diffusion screening tests using selected antimicrobial agents (1). Each Klebsiella pneumoniae, K. oxytoca, or Escherichia coli isolate should be considered a potential ESBL-producer if the test results are as follows:
|cefpodoxime < 22 mm||cefpodoxime > 2 µg/ml|
|ceftazidime < 22 mm||ceftazidime > 2 µg/ml|
|aztreonam < 27 mm||aztreonam > 2 µg/ml|
|cefotaxime < 27 mm||cefotaxime > 2 µg/ml|
|ceftriaxone < 25 mm||ceftriaxone > 2 µg/ml|
The sensitivity of screening for ESBLs in enteric organisms can vary depending on which antimicrobial agents are tested. The use of more than one of the five antimicrobial agents suggested for screening will improve the sensitivity of detection. Cefpodoxime and ceftazidime show the highest sensitivity for ESBL detection.
NCCLS recommends performing phenotypic confirmation of potential ESBL-producing isolates of K. pneumoniae, K. oxytoca, or E. coli by testing both cefotaxime and ceftazidime, alone and in combination with clavulanic acid (1). Testing can be performed by the broth microdilution method or by disk diffusion. For MIC testing, a decrease of > 3 doubling dilutions in an MIC for either cefotaxime or ceftazidime tested in combination with 4 µg/ml clavulanic acid, versus its MIC when tested alone, confirms an ESBL-producing organism. For disk diffusion testing, a > 5 mm increase in a zone diameter for either antimicrobial agent tested in combination with clavulanic acid versus its zone when tested alone confirms an ESBL-producing organism.
How should laboratory personnel test for cefotaxime and ceftazidime in combination with clavulanic acid?
NCCLS suggests making disks by adding 10 µl of a 1000 µg/ml stock solution of clavulanic acid to cefotaxime and ceftazidime disks each day of testing (1). In the future, commercial manufacturers of antimicrobial disks may produce disks containing cefotaxime and ceftazidime with clavulanic acid. Until commercial disks are available, SmithKline Beecham can provide clinical laboratories with clavulanic acid powder for routine testing of clinical isolates (please contact Karen Dobbs [U.K.] 44-1-279-627-562, fax 44-1-279-627-567. Alternatively, contact Rosaria Fajardo [U.S.] 1-610-270-6854, fax 1-610-270-6798. In your request, provide your name, address, telephone and fax numbers, and the name of the compound required).
K. pneumoniae ATCC 700603 (positive control) and E. coli ATCC 25922 (negative control) should be used for quality control of ESBL tests (1).
Can an ESBL be present in an isolate of K. pneumoniae that is resistant to ceftazidime and/or cefotaxime, but demonstrates no clavulanic acid effect in the phenotypic confirmatory test?
Yes. The phenotypic confirmatory test does not detect all ESBLs. Some organisms with ESBLs contain other β-lactamases that can mask ESBL production in the phenotypic test, resulting in a false-negative test. These β-lactamases include AmpCs and inhibitor-resistant TEMs (IRTs). Hyper-production of TEM and/or SHV β-lactamases in organisms with ESBLs also may cause false-negative phenotypic confirmatory test results. Currently, detection of organisms with multiple β-lactamases that may interfere with the phenotypic confirmatory test can only be accomplished using isoelectric focusing and DNA sequencing, methods that are not usually available in clinical laboratories.
If an isolate is confirmed as an ESBL-producer by the NCCLS-recommended phenotypic confirmatory test procedure, all penicillins, cephalosporins, and aztreonam should be reported as resistant. This list does not include the cephamycins (cefotetan and cefoxitin), which should be reported according to their routine test results. If an isolate is not confirmed as an ESBL-producer, current recommendations suggest reporting results as for routine testing. Do not change interpretations of penicillins, cephalosporins, and aztreonam for isolates not confirmed as ESBLs.
Yes. Other isolates of Enterobacteriaceae, such as Salmonella species and Proteus mirabilis, and isolates of Pseudomonas aeruginosa produce ESBLs. However, at this time, methods for screening and phenotypic confirmatory testing of these isolates have not been determined by NCCLS.
- National Committee for Clinical Laboratory Standards. 1999. Performance standards for antimicrobial susceptibility testing. NCCLS approved standard M100-S9. National Committee for Clinical Laboratory Standards, Wayne, PA.